A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy

  • End date
    Jun 16, 2022
  • participants needed
  • sponsor
    Boehringer Ingelheim
Updated on 22 September 2021
geographic atrophy
diabetic retinopathy
corrected visual acuity
age-related macular degeneration


This is a study in adults with geographic atrophy, an advanced form of age-related macular degeneration. The purpose of this study is to find out how well different doses of BI 754132 are tolerated.

The participants are in the study for about 4 months. During this time, they visit the study site about 10 times. Participants receive 1 injection of BI 754132 directly into one of the eyes affected by geographic atrophy. In this study, BI 754132 is given to humans for the first time.

The doctors compare how well participants tolerate the different doses of BI 754132. The doctors also regularly check the general health of the participants.

Condition age-related macular degeneration, Maculopathy, Macular Degeneration
Treatment BI 754132
Clinical Study IdentifierNCT04002310
SponsorBoehringer Ingelheim
Last Modified on22 September 2021


Yes No Not Sure

Inclusion Criteria

Men and women with Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD): the GA lesion at least 0.75 disk areas in size
Fellow eye is not required to have GA
Best Corrected Visual Acuity (BCVA)
Age than 50 years
Single Rising Dose (SRD) part: BCVA of 20/100 to 20/400 Snellen (corresponding to 19 to 53 letters in the ETDRS chart) in the study eye equivalent measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol
Multiple Dosing (MD) part: BCVA of 20/100 or worse in the Snellen chart (equivalent to 53 letters or worse in the ETDRS chart)
Best-corrected VA in the non-study eye must have a better best-corrected VA compared to the study-eye, if both eyes are eligible and have identical VA the investigator may select the study eye
Women of childbearing potential (WOCBP) cannot be included. Men able to father a child must be ready and able to use highly effective methods of birth control per International Council on Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information
Signed informed consent consistent with International Council on Harmonisation Good Clinical Practice (ICH GCP) guidelines and local legislation prior to participation in the trial, which includes medication washout and restrictions
Not under any administrative or legal supervision or under institutionalization due to regulatory or juridical order

Exclusion Criteria

GA in either eye because of causes other than AMD
History of choroidal neovascularization (CNV) in the study eye and in the fellow eye
Previous treatment in the study eye for GA secondary to AMD within 6 months prior to screening visit (ongoing therapy with vitamin and mineral supplements is allowed)
Additional eye disease in the study eye that could compromise
best corrected VA (BCVA) with visual field loss
uncontrolled glaucoma intraocular pressure (IOP>24)
clinically significant diabetic maculopathy
history of ischemic optic neuropathy or retinal vascular occlusion
symptomatic vitreomacular traction
genetic disorders such as retinitis pigmentosa)
history of high myopia > 8 diopters in the study eye and
anterior segment and vitreous abnormalities in the study eye that would preclude adequate observation with Spectral Domain Optical Coherence Tomography (SD-OCT)
Any prior intraocular surgery in the study eye other then uneventful lens replacement for cataract within 3 months prior to screening
Aphakia or total absence of the posterior capsule. Yttrium aluminum garnet (YAG) laser capsulotomy permitted, more than 3 month prior to enrollment in the study eye
Current or planned use of medications known to be toxic to the retina, lens or optic nerve (e.g. desferoximine, chloroquine/hydrochloroquine, chlorpromazine, phenothiazines, tamoxifen, nicotinic acid, and ethambutol)
Significant disease or other medical conditions (as determined by medical history, examination and clinical investigations at screening) that may, in the opinion of the investigator result in the any of the following
Put the patient at risk because of participation in the study
Influence the results of the study
Cause concern regarding the patient's ability to participate in the study, e.g. cardiac (including tachycardia), gastro-intestinal, hepatic, renal, metabolic, dermatologic, neurological, haematological, oncological and psychiatric
Patients with malignancy for which the patient has undergone resection, radiation or chemotherapy within past 5 years. Patients with treated basal cell carcinoma or fully cured squamous cell carcinoma are allowed
Known hypersensitivity to any of the ingredients used in the Investigational Medical Product (IMP) formulation, or any of the medications used
Active intraocular inflammation in the study eye
Active infectious conjunctivitis in either eye
Further exclusion criteria apply
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note